RVNC — Revance Therapeutics Share News
0.000.00%
Last trade - 00:00- $379.98m
- $637.94m
- $234.04m
Brief: Crown Laboratories And Revance Amend A&R Merger Agreement
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Kratos, Forward Air, Bank stocks
U.S. STOCKS ON THE MOVE-Henry Schein, natgas firms, Citigroup
Deals of the day-Mergers and acquisitions
Teoxane makes higher offer for Botox rival maker Revance (updated)
Revance Therapeutics gains after Teoxane's buyout proposal
Brief: Teoxane SA Announces Superior Proposal To Acquire Revance Therapeutics For $3.60 Per Share In Cash
Teoxane offers superior proposal to acquire Revance Therapeutics
Brief: Crown Laboratories Commences Friendly Tender Offer For All Outstanding Common Shares Of Revance Therapeutics At $3.10 Per Share
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Apollo, Hershey, RH
U.S. STOCKS ON THE MOVE-Warner Bros, Seres Therapeutics, Enterprise Bancorp
Revance Therapeutics falls after agreeing lower-priced buyout deal
Deals of the day-Mergers and acquisitions
Revance agrees to lower priced buyout offer by Crown Laboratories (updated)
Revance agrees to lower-priced buyout offer by Crown Laboratories
Brief: Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Revance Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary